Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Entyvio
Pharma
Takeda treads water despite loss of exclusivity on Vyvanse
Despite the recent loss of exclusivity on Takeda's ADHD med Vyvanse, the company's portfolio of newer products continues to hold the sales line.
Fraiser Kansteiner
Feb 1, 2024 1:56pm
FDA signs off on Takeda's subcutaneous version of Entyvio
Sep 28, 2023 11:32am
Takeda expects patent expirations to weigh on earnings
May 12, 2023 11:10am
The top 10 pharma drug brand ad spenders for 2022
May 1, 2023 3:00am
AbbVie's Skyrizi aces ulcerative colitis induction study
Mar 23, 2023 10:57am
AbbVie continues top TV drug ad spender reign
Oct 10, 2022 10:57am